Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INTEGRATE

Financiado

Personalised Medicine for Intervertebral Disc Regeneration Integrating Profilin...

Personalised Medicine for Intervertebral Disc Regeneration Integrating Profiling Predictive Modelling and Gene Activated Biomaterials Lower back pain is a global epidemiological and socioeconomic problem. Biomaterial and cell-based therapies have been pursued for the treatment of degenerated intervertebral disc (IVD), with a number of clinical trials underway. H... ver más

31/08/2025

TRINITY COLLEGE DU...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

THE PROVOST FELLOWS FOUNDATION SCHOLARS THE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-03-03

ERC-2019-COG: ERC Consolidator Grant

I+D

Cerrada hace 5 años

0% 100% 100%

3 Participantes

TRINITY COLLEGE DUBLIN

1.75M€ | Lider

JEMA ENERGY

499.08K€ | Participante

NUID UCD

245.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FETALIX FETALIX - REJUVENATING THE SPINE TO SET YOU FREE 75K€ Cerrado

Disc4All Training network to advance integrated computational simulat... 4M€ Cerrado

EUIN2017-89399 SIMULACION Y PLATAFORMA DE ANALISIS DE DEGENERACION DE DISCO... 25K€ Cerrado

CTQ2015-73105-EXP DEDALO: HACIA UN NUEVO PARADIGMA EN LA MEDICINA PERSONALIZAD... 54K€ Cerrado

VitaDisc A novel non-invasive therapy based on injectable viscous gel... 5M€ Cerrado

iDISC Rejuvenation of the Intervertebral Disc Using Self-Healing B... 150K€ Cerrado

Duración del proyecto: 65 meses Fecha Inicio: 2020-03-03
Fecha Fin: 2025-08-31

Líder del proyecto

THE PROVOST FELLOWS FOUNDATION SCHOLARS THE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Lower back pain is a global epidemiological and socioeconomic problem. Biomaterial and cell-based therapies have been pursued for the treatment of degenerated intervertebral disc (IVD), with a number of clinical trials underway. However, the degenerated intervertebral disc has a distinct environment (e.g. altered oxygen, glucose, acidity, inflammatory cytokine levels) that is unique to an individual (i.e. patient-specific) and will ultimately determine the likelihood and rate at which regeneration can occur. A one size fits all approach will lead to the failure to demonstrate efficacy of advanced therapies, as they are not being designed or personalised for individual patients. This proposal envisions a future whereby advanced gene activated cell therapies are personalised (targeting regeneration or modulating inflammation) to treat back pain based on knowing the individuals unique disc microenvironment. This will be achieved through profiling of individual patient disc microenvironmental factors, with in vitro screening and in silico modelling to design cell therapies and predict regeneration outcomes (Aim 1) combined with the development of tailored functionalised gene activated biomaterials (Aim 2), to enhance matrix formation and modulate the inflammatory processes (Aim 3). Gene-based therapy offers several advantages over direct delivery of proteins or small molecules, among them the possibility of sustained efficacy and endogenous synthesis of growth factors or suppression of inflammatory factors and pathways. The platform technology (personalised gene activated biomaterials to regulate regeneration and inflammation) and knowledge (tailoring cell therapies to suit patient-specific microenvironments) generated through this research are beyond the current state-of-the-art and will provide a significant transformative scientific and clinical step change opening new horizons in minimally-invasive therapeutic strategies.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores